STE · STERIS plc
$214.13
+3.49 (+1.66%)
At close · Jul 24
Market Cap
$20.89B
Shares
97.60M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$5.94B
+8.7%
FY2026
Net Income
$782.3M
+27.3%
FY2026
Gross Margin
44.25%
+0.2pp
FY2026
Operating Margin
18.56%
+2.7pp
FY2026
Diluted EPS
$7.93
+27.9%
FY2026
Operating Cash Flow
$1.34B
+16.8%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2027 (G) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| — | $5.94B | $5.46B | $5.14B | $4.96B | $4.59B | $3.11B | $3.03B | $2.78B | $2.62B | |
| — | $3.31B | $3.06B | $2.92B | $2.8B | $2.57B | $1.76B | $1.71B | $1.61B | $1.53B | |
| — | $2.63B | $2.4B | $2.22B | $2.16B | $2.02B | $1.34B | $1.32B | $1.18B | $1.09B | |
| — | 44.25% | 44.01% | 43.17% | 43.56% | 43.98% | 43.22% | 43.55% | 42.25% | 41.71% | |
| — | $112.9M | $107.6M | $103.7M | $101.58M | $87.94M | $66.33M | $65.55M | $63.04M | $60.78M | |
| — | $1.41B | $1.33B | $1.25B | $1.3B | $1.5B | $731.32M | $716.73M | $669.94M | $631.98M | |
| — | $268.2M | $276.2M | $268.3M | $379.75M | $368.7M | $86.51M | $74.53M | $98.75M | $70.2M | |
| — | $486.5M | $476.2M | $565.2M | $552.9M | $553.1M | $219.24M | $197.24M | $225.92M | $178.33M | |
| — | $3.4M | $62.3M | $44.4M | $485K | $48K | -$3.03M | $3.14M | $40.71M | $103K | |
| — | $1.52B | $1.54B | $1.38B | $1.89B | $1.59B | $794.73M | $782.95M | $763.96M | $692.86M | |
| — | $1.1B | $866.6M | $836.1M | $268.19M | $425.62M | $548.37M | $536.97M | $411.47M | $399.88M | |
| — | 18.56% | 15.87% | 16.27% | 5.41% | 9.28% | 17.65% | 17.72% | 14.79% | 15.26% | |
| — | $1.59B | $1.34B | $1.4B | $821.08M | $978.72M | $767.61M | $734.21M | $637.39M | $578.22M | |
| — | $60.7M | $86.3M | $144.35M | $107.99M | $89.59M | $37.18M | $40.28M | $45.02M | $50.63M | |
| — | -$54.4M | -$70.4M | -$133.3M | -$110.84M | -$111.12M | -$30.84M | -$38.29M | -$42M | -$44.9M | |
| — | $1.05B | $796.2M | $702.8M | $157.35M | $314.5M | $517.53M | $498.68M | $369.47M | $354.98M | |
| — | $262.2M | $184.7M | $149.5M | $51.54M | $71.63M | $120.66M | $90.88M | $64.39M | $63.36M | |
| — | $782.3M | $614.6M | $378.2M | $107M | $243.9M | $397.4M | $407.61M | $304.05M | $290.92M | |
| — | 13.18% | 11.26% | 7.36% | 2.16% | 5.32% | 12.79% | 13.45% | 10.93% | 11.1% | |
| — | $2.8M | $1.4M | $1.8M | -$1.22M | -$1.02M | -$530K | $200K | $1.03M | $707K | |
| — | $961.5M | $651M | $370.3M | -$3.87M | $95.32M | $571.62M | $331.92M | $134.56M | $543.3M | |
| USD/shares | — | $7.97 | $6.24 | $3.83 | $1.07 | $2.50 | $4.66 | $4.81 | $3.59 | $3.42 |
| USD/shares | $11.10 – $11.30* | $7.93G | $6.20 | $3.81 | $1.07 | $2.48 | $4.63 | $4.76 | $3.56 | $3.39 |
| shares | — | 98.2M | 98.6M | 98.8M | 99.71M | 97.54M | 85.2M | 84.78M | 84.58M | 85.03M |
| shares | — | 98.7M | 99.1M | 99.4M | 100.25M | 98.33M | 85.9M | 85.64M | 85.47M | 85.71M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2026: $1.04B in buybacks, $1.48B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Devices median 2.14×
EV/EBIT
—
Medical Devices median 21.03×
P/E (TTM)
26.99×
Medical Devices median 27.62×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Healthcare Segment | $4,208,600,000 | $3,878,700,000 | $3,613,000,000 | $3,085,131,000 | — | — | — | — |
| Applied Sterilization Technologies | $1,138,500,000 | $1,038,600,000 | $954,000,000 | $914,431,000 | $685,912,000 | $627,147,000 | $555,127,000 | $513,287,000 |
| Life Science Member | $588,800,000 | $542,300,000 | $571,700,000 | $536,704,000 | $467,552,000 | $416,939,000 | $378,558,000 | $361,590,000 |
| Healthcare | — | $3,878,671,000 | $3,613,019,000 | $3,085,131,000 | $1,954,055,000 | $1,986,809,000 | $1,848,485,000 | — |
| Healthcare Products Member | — | — | — | — | — | $1,423,198,000 | $1,338,428,000 | $1,276,054,000 |
| Healthcare Specialty Services | — | — | — | — | — | $563,611,000 | $510,057,000 | $469,065,000 |
By Geography (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| United States | $4,333,800,000 | $4,007,600,000 | $3,751,400,000 | $3,254,373,000 | $2,943,950,000 | $2,227,038,000 | $2,211,722,000 | $1,976,814,000 |
| Other Foreign Locations | $1,493,700,000 | $1,344,600,000 | $1,304,600,000 | $1,207,601,000 | $1,197,589,000 | $808,576,000 | $755,352,000 | $748,572,000 |
| Ireland | $108,500,000 | $107,300,000 | $82,700,000 | $74,292,000 | $81,864,000 | $71,905,000 | $63,821,000 | $56,784,000 |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Product | $3,060,100,000 | $2,871,600,000 | $2,764,000,000 | $2,363,754,000 | $2,194,620,000 | $1,443,540,000 | $1,402,788,000 | $1,296,025,000 |
| Service | $2,875,800,000 | $2,587,900,000 | $2,374,700,000 | $2,172,512,000 | $2,028,783,000 | $1,663,979,000 | $1,628,107,000 | $1,486,145,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|
| Operating Segment All | $699,380,000 | $628,699,000 | $556,522,000 | $509,807,000 |
| Healthcare | $427,089,000 | $420,709,000 | $387,465,000 | — |
| Applied Sterilization Technologies | $310,648,000 | $270,917,000 | $221,828,000 | $196,297,000 |
| Life Science Member | $180,796,000 | $144,088,000 | $132,129,000 | $123,889,000 |
| Operating Segment Corp and Other | -$219,153,000 | -$207,015,000 | -$184,900,000 | -$162,999,000 |
| Healthcare Products Member | — | $356,419,000 | $323,684,000 | $294,162,000 |
| Healthcare Specialty Services | — | $64,217,000 | $64,222,000 | $58,458,000 |
Operating Margin by Segment (%)
| Component | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|
| Applied Sterilization Technologies | 45.3% | 43.2% | 40% | 38.2% |
| Life Science Member | 38.7% | 34.6% | 34.9% | 34.3% |
| Healthcare | 21.9% | 21.2% | 21% | — |
| Healthcare Products Member | — | 25% | 24.2% | 23.1% |
| Healthcare Specialty Services | — | 11.4% | 12.6% | 12.5% |
Key facts
CIK
1757898
CUSIP
G8473T100
13F (30d)
181 filings
181 filers
Visit website
Investor relations